论文部分内容阅读
AIM:To estimate the effect of a therapeutic vaccine againstpancreatic carcinoma based on dendritic cell(DC)vaccinemodified with tumor lysate and Interleukin-18 gene.METHODS:The BALB/C mice model of pancreatic carcinomawas induced with DMBA.DC vaccine was constructed throughpulsed with tumor lysate and transfected by the recombinantadenoviral vector encoding IL-18 gene.The immnotherapeuticeffects of DC vaccine on mice with pancreatic carcinomawere assessed(divided into DC-IL18-Lysate group,DC-Lysategroup,DC-IL18 group,DC group,PBS group).RESULTS:After vaccination of the DC vaccine,theconcentration of IL-18 and IFN-γ were 2161±439 ng·L~(-1)and 435±72 ng·L~(-1)in DC-IL18-Lysate group and there wassignificant difference compared with other groups(P<0.01).After vaccination of the DC vaccine,the transplanted tumorswere observed on 30 days in DC-Lysate groups,on 16 daysin DC-IL18 groups,on 3 days in control group,but miceremained tumor-free for at least 50 days in DC-IL18-Lysategroup and there was significant difference between DC-IL18-Lysate group and other groups(P<0.01).The median survivalexceeds 62 days in DC-IL18-Lysate group.But the mediansurvival was 48.6 days in DC-Lysate group,33 days in DC-ILl8 group,17 days in PBS group.The survival period wasobviously prolonged in DC-IL18-Lysate group than in othergroups(P<0.05,P<0.01).The weight of pancreatic tumorwas 0.22±0.083 g in DC-IL18-Lysate group,1.45±0.74 gin DC-Lysate group,1.89±1.34 g in DC-IL18 group,3.0±1.6 g in DC group,2.9±2.0 g in PBS group and the weightof tumor obviously reduced in DC-IL18-Lysate group thanin other groups(P<0.05,P<0.01).CONCLUSION: DC vaccine modified with tumor lysate and Interleukin-18 gene can induce a specific and effective immune response against pancreatic carcinoma cell.
AIM: To estimate the effect of a therapeutic vaccine against pancreatic carcinoma based on dendritic cell (DC) vaccine modified with tumor lysate and Interleukin-18 gene. METHODS: The BALB / C mice model of pancreatic carcinoma was induced with DMBA. tumor lysate and transfected by the recombinant adenoviral vector encoding IL-18 gene. The immnotherapeutic effects of DC vaccine on mice with pancreatic carcinoma assessment (DC-IL18-Lysate group, DC-IL18 group, DC group, PBS group) .RESULTS: After vaccination of the DC vaccine, the concentration of IL-18 and IFN-γ were 2161 ± 439 ng · L -1 and 435 ± 72 ng · L -1 in DC-IL18-Lysate group and there wassignificant difference compared with other groups (P <0.01). After vaccination of the DC vaccine, the transplanted tumors were observed for 30 days in DC-Lysate groups, on 16 days in DC-IL18 groups, on 3 days in control group, but miceremained tumor-free for at least 50 days in DC-IL18-Lysategroup and There was a significant difference between DC-IL18-Lysate group and other groups (P <0.01). The median survivable was 62 days in DC-IL18-Lysate group. The mediansurvival was 48.6 days in DC-Lysate group, 33 days in DC- ILl8 group, 17 days in PBS group. The survival period wasobviously prolonged in DC-IL18-Lysate group than in other groups (P <0.05, P <0.01). The weight of pancreatic tumor was 0.22 ± 0.083 g in DC-IL18-Lysate group , 1.45 ± 0.74 gin DC-Lysate group, 1.89 ± 1.34 g in DC-IL18 group, 3.0 ± 1.6 g in DC group, 2.9 ± 2.0 g in PBS group and the weight of tumor significantly reduced in DC-IL18-Lysate group thanin other groups (P <0.05, P <0.01) .CONCLUSION: DC vaccine modified with tumor lysate and Interleukin-18 gene can induce a specific and effective immune response against pancreatic carcinoma cells.